(0.33%) 5 116.74 points
(0.32%) 38 363 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.51%) $2.03
(0.30%) $2 354.30
(0.42%) $27.65
(4.11%) $960.00
(-0.27%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.48%
@ $234.68
発行日: 27 4月 2024 @ 00:42
リターン: 2.18%
前回のシグナル: 4月 26 - 04:08
前回のシグナル:
リターン: -0.60 %
Live Chart Being Loaded With Signals
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 127 232 |
平均出来高 | 470 161 |
時価総額 | 11.28B |
EPS | $0 ( 2024-02-21 ) |
次の収益日 | ( $5.63 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 12.10 |
ATR14 | $4.71 (1.96%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-23 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-24 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-24 | Rothblatt Martine A | Buy | 3 600 | Common Stock |
2024-04-24 | Rothblatt Martine A | Sell | 36 | Common Stock |
2024-04-24 | Rothblatt Martine A | Sell | 145 | Common Stock |
INSIDER POWER |
---|
-42.40 |
Last 100 transactions |
Buy: 76 860 | Sell: 189 720 |
ボリューム 相関
United Therapeutics Corp 相関
10 最も負の相関 | |
---|---|
GAINL | -0.934 |
APOP | -0.93 |
TDAC | -0.928 |
RMRM | -0.876 |
ISNS | -0.861 |
CMLF | -0.852 |
INZY | -0.826 |
NTEC | -0.819 |
MAGS | -0.814 |
SVOK | -0.813 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
United Therapeutics Corp 相関 - 通貨/商品
United Therapeutics Corp 財務諸表
Annual | 2023 |
収益: | $2.33B |
総利益: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2023 |
収益: | $2.33B |
総利益: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2022 |
収益: | $1.94B |
総利益: | $1.79B (92.42 %) |
EPS: | $15.98 |
FY | 2021 |
収益: | $1.69B |
総利益: | $1.56B (92.73 %) |
EPS: | $10.60 |
Financial Reports:
No articles found.
United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。